CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Percutaneous Tibial Nerve Stimulation

Defines medical necessity criteria, prior authorization expectations, covered indication (overactive bladder syndrome) and exclusions (fecal incontinence), and the CPT code applicable for percutaneous posterior tibial nerve stimulation for BlueCHiP for Medicare and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Percutaneous Tibial Nerve Stimulation

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for BlueCHiP for Medicare (recommended for Commercial); document specialist evaluation, failed behavioral therapy and ≥2 medication trials, willingness to attend sessions, and voiding diary evidence of OAB.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes to this policy at this time.

1Covered Indication (OAB)

1Excluded Indication (fecal incontinence)

12Initial weekly treatment sessions

Coverage Summary

Percutaneous tibial nerve stimulation (PTNS) is covered for the treatment of overactive bladder (OAB) when the medical criteria are met; PTNS is not covered for fecal incontinence because devices are not FDA-cleared for that indication. The typical initial course is one 30-minute session per week for 12 weeks, with individualized maintenance thereafter. Prior authorization is expected (required for BlueCHiP for Medicare and recommended for Commercial products) and providers must document specialist evaluation and required conservative and medication trials before coverage is allowed.

Policy thresholds and quick facts

Medication trial durationAt least two appropriate medications administered for 4 to 8 weeks

Initial treatment courseOne 30-minute session per week for 12 weeks (initial series of 12 weekly office-based treatments)

Retreatment eligibility threshold>50% decrease in OAB/OBS symptoms with the initial treatment (then relapse required)

Scope summaryDefines medical necessity criteria, prior authorization expectations, covered indication (overactive bladder syndrome) and exclusions (fecal incontinence); CPT code 64566 covered when criteria met

Medical-Necessity Criteria

Medical Criteria for PTNS (covered indication)

PTNS is considered reasonable and necessary when ALL of the following are met:

An evaluation by an appropriate specialist (usually a urologist or urogynecologist) has been performed and the specialist has determined the patient is a candidate for PTNS.

The medical record documents that the beneficiary has been compliant with and failed a trial of symptom-appropriate behavioral therapy of sufficient length to evaluate potential efficacy.

The medical record documents that the beneficiary has been compliant with and has failed or been unable to tolerate a trial of at least two appropriate medications administered for four (4) to eight (8) weeks.at least two medications for 4 to 8 weeks

The beneficiary has documented a willingness to attend in-office treatment sessions, to comply with behavioral therapies, and to continue maintaining voiding diaries including documentation of behavioral therapy compliance.

The voiding diary shows continued evidence of overactive bladder syndrome (OAB).

Treatment plan consists of an initial course of one 30-minute session per week for 12 weeks.one 30-minute session per week for 12 weeks

Maintenance / Retreatments

Conditions for allowing treatments for relapse:

Retreatments for relapse are allowed only for patients who achieved a greater than 50% decrease in OAB symptoms with the initial treatment and then relapsed.> 50% decrease in OAB symptoms

Not covered / investigational

PTNS is considered investigational / contract exclusion when used for:

Treatment of fecal incontinence (not FDA-cleared for this indication).not FDA-cleared

Contract exclusion for fecal incontinence; not covered

Provider Actions

Prior Authorization

Prior authorization requirement

Prior authorization is required for BlueCHiP for Medicare and is recommended for Commercial products. Participating providers must obtain prior authorization via the online tool.

Affected code(s): 64566
Prior authorization required for BlueCHiP for Medicare; recommended for Commercial products
Obtain prior authorization via the online tool for participating providers

Documentation Required

Specialist evaluation and documentation

Provider must document an evaluation by an appropriate specialist (usually a urologist or urogynecologist) determining the patient is a candidate for PTNS. The medical record must document compliance with and failure of symptom-appropriate behavioral therapy of sufficient length, and compliance with and failure of or intolerance to at least two appropriate medications administered for four (4) to eight (8) weeks. Document the beneficiary's willingness to attend in-office treatment sessions, comply with behavioral therapies, and continue maintaining voiding diaries showing evidence of overactive bladder.

Codes: 64566
Specialist evaluation (urologist or urogynecologist) determining candidacy
Documentation of compliance with and failure of symptom-appropriate behavioral therapy
Documentation of compliance with and failure of or intolerance to ≥2 appropriate medications for 4–8 weeks
Patient willingness to attend in-office sessions and comply with behavioral therapies
Voiding diary showing continued evidence of overactive bladder

Billing Rule

Treatment session billing

Initial treatment consists of one 30-minute office-based session once weekly for 12 weeks. CPT code 64566 (posterior tibial neurostimulation, percutaneous needle electrode, single treatment; includes programming) is the covered code when the medical criteria are met.

Codes: 64566
Initial course: 12 weekly 30-minute sessions

Denial Risk

Exclusion for fecal incontinence

PTNS for fecal incontinence is not FDA-cleared for that indication and is considered investigational and a contract exclusion. Claims for PTNS when billed for treatment of fecal incontinence may be excluded or denied.

Background

PTNS is an electrical neuromodulation technique in which a percutaneous needle is inserted above the medial malleolus to stimulate the posterior tibial nerve and deliver low-voltage electrical stimulation (typically producing sensory and motor responses). The FDA-cleared indication is for overactive bladder and associated symptoms (urinary frequency, urgency, urge incontinence); PTNS devices are not FDA-cleared for fecal incontinence.

PTNS is typically delivered as an initial series of 12 weekly office-based treatments of approximately 30 minutes each, followed by an individualized maintenance schedule. Noninvasive surface electrode approaches also exist, and PTNS is less invasive than sacral neuromodulation (which requires implantation of a permanent generator and leads).

Definitions: Overactive bladder (OAB) — voiding dysfunction characterized by urinary frequency, urgency, urge incontinence, and nonobstructive retention. PTNS — percutaneous tibial nerve stimulation; percutaneous electrical stimulation of the posterior tibial nerve near the ankle.

Evidence summary: multiple systematic reviews and randomized trials support the efficacy of PTNS for overactive bladder. Published systematic reviews and meta-analyses (references 2–6) and randomized controlled trials (including sham-controlled and active-comparator trials such as SUmiT and comparisons versus tolterodine; references 7–10) report benefit of PTNS in OAB.

Name	Identifier/Type
Posterior Tibial Nerve Stimulation for Voiding Dysfunction	LCDId-33396, type LCD

Revision History

coverage_criteriaLatest

PTNS is reasonable and necessary for overactive bladder when all criteria met: specialist evaluation confirming candidacy; failed compliant trial of symptom-appropriate behavioral therapy; failed or intolerant to at least two appropriate medications given for 4–8 weeks; willingness to attend in-office sessions and maintain voiding diaries showing continued OAB; treatment plan of one 30-minute session per week for 12 weeks.

maintenance_retreatmentLatest

Retreatments for relapse allowed only for patients who achieved >50% decrease in OAB symptoms with the initial treatment and then relapsed.

coverage_exclusionLatest

PTNS for fecal incontinence is investigational and a contract exclusion because PTNS devices are not FDA-cleared for that indication.

procedure_description_and_courseLatest

PTNS involves percutaneous needle insertion near the medial malleolus to stimulate the posterior tibial nerve with low-voltage electrical stimulation; recommended initial course is 12 weekly office-based 30-minute treatments followed by individualized maintenance.

billing_codeLatest

CPT 64566 (posterior tibial neurostimulation, percutaneous needle electrode, single treatment; includes programming) is covered when criteria are met; prior authorization is required for BlueCHiP for Medicare and recommended for Commercial products.